ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Holdings Raised by GAMMA Investing LLC

GAMMA Investing LLC lifted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 17,558.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 95,002 shares of the specialty pharmaceutical company’s stock after purchasing an additional 94,464 shares during the quarter. GAMMA Investing LLC’s holdings in ANI Pharmaceuticals were worth $6,360,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. US Bancorp DE grew its position in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after purchasing an additional 531 shares during the last quarter. KBC Group NV boosted its position in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after acquiring an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in ANI Pharmaceuticals during the 4th quarter valued at about $166,000. Rafferty Asset Management LLC bought a new position in ANI Pharmaceuticals during the 4th quarter valued at about $200,000. Finally, Bridgefront Capital LLC bought a new position in ANI Pharmaceuticals during the 4th quarter valued at about $204,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target for the company. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock. Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a research note on Monday, April 21st. Finally, Guggenheim reiterated a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $80.13.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Ori Gutwerg sold 881 shares of the firm’s stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the sale, the senior vice president now owns 89,897 shares of the company’s stock, valued at $5,400,112.79. This trade represents a 0.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the sale, the vice president now owns 80,145 shares in the company, valued at approximately $5,526,799.20. The trade was a 0.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,681 shares of company stock worth $347,638 in the last three months. 11.10% of the stock is owned by insiders.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $63.18 on Tuesday. The company’s 50 day moving average is $65.05 and its 200-day moving average is $61.00. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $77.00. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.37 billion, a P/E ratio of -114.87 and a beta of 0.55.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $197.12 million during the quarter, compared to analysts’ expectations of $179.75 million. During the same quarter in the previous year, the company earned $0.82 EPS. The business’s quarterly revenue was up 43.4% compared to the same quarter last year. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.